Wolff Wiese Magana’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wolff Wiese Magana’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-102	Closed	-$9K	–	801
2021 Q4	$9K	Hold	102	–	–	0.01%	560
2021 Q3	$8K	Sell	102 -14	-12%	-$1.1K	0.01%	550
2021 Q2	$10K	Hold	116	–	–	0.01%	506
2021 Q1	$9K	Sell	116 -119	-51%	-$9.72K	0.01%	488
2020 Q4	$21K	Buy	+235	New	+$18.6K	0.02%	368

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Wolff Wiese Magana's BMRN Position: Q1 2022 in Review

Wolff Wiese Magana sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2022, closing a stake of 102 shares — an estimated $9K sold.

Wolff Wiese Magana first reported a position in BMRN in Q4 2020 and held it in 5 quarters. The position peaked at $21K in Q4 2020. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

Wolff Wiese Magana reported no remaining BioMarin Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Wolff Wiese Magana sold 102 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $9K.
Wolff Wiese Magana first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 5 quarters.
Wolff Wiese Magana's BioMarin Pharmaceuticals position peaked at $21K in Q4 2020.
560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on Wolff Wiese Magana's 13F filing for Q1 2022, filed 9 May 2022.